semaglutide adolescent obesity trial 2022 GLP-1 prescribing among teens with Weight Loss Drug Wegovy Led

This cardiovascular protection has been demonstrated at the 2.4 mg Wegovy dose, not at the lower Ozempic doses

Semaglutide GLP-1 helps to suppress appetite, slow stomach emptying, and improve insulin sensitivity, making it easier to reduce calorie intake and manage hunger

Key Takeaways BCBS coverage for Zepbound varies by state and plan type: There is no single BCBS policy each state affiliate and employer group sets its own formulary Prior authorization is almost always required: Even plans that cover Zepbound require clinical documentation before approving claims BMI thresholds typically apply: Most BCBS plans require a BMI 30, or 27 with a weight-related comorbidity like type 2 diabetes or hypertension Some BCBS affiliates have dropped GLP-1 coverage entirely: BCBS Michigan removed all GLP-1 weight loss drugs from fully insured commercial plans starting January 2025 Research-grade tirzepatide exists for laboratory use: Not a substitute for prescription medication, but available at significantly lower cost for research applications Zepbound (tirzepatide) launched in late 2023 as Eli Lilly's dedicated weight management version of Mounjaro

Start your intake Clinical Evidence: Average Semaglutide Weight Loss Outcomes The STEP trials, which evaluated semaglutide for weight management in adults without diabetes, revealed average weight reductions of 9.2% to 12.4% over 68 weeks at standard doses